Rahul Kumar

In a historic Phase 3 readout at WCLC 2026, the pH-sensitive recycling anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) demonstrated an unprecedented median overall survival of 18.5 months versus 10.0 months for standard docetaxel in post-IO metastatic squamous NSCLC (HR 0.58, p = 0.0001), rewriting 15 years of thoracic oncology practice.

The US FDA has approved amivantamab (Rybrevant) plus lazertinib (Lazcluze) for first-line EGFR-mutated advanced NSCLC based on Phase 3 MARIPOSA data demonstrating a 7.1-month PFS advantage over osimertinib (Tagrisso), triggering a global debate over efficacy versus infusion toxicity.

Cullinan Therapeutics and Taiho Pharmaceutical have submitted an NDA to the US FDA for oral zipalertinib in front-line EGFR exon 20 insertion NSCLC, backed by Phase 3 REZILIENT3 data demonstrating a 52% reduction in progression or death.

In a historic clinical oncology milestone, the PD-1/VEGF bispecific antibody ivonescimab became the first therapy in history to outperform pembrolizumab monotherapy head-to-head in first-line advanced NSCLC, extending median PFS to 11.14 months vs. 5.82 months.

Illumina has launched the benchtop MiSeq i100 and i100 Plus sequencing systems, eliminating dry-ice cold-chain logistics and slashing NGS turnaround times to under four hours for infectious disease and targeted panels.

Over-subscribed funding round led by Wellington Management will expand worldwide field service infrastructure and commercial production for the AVITI and AVITI24 multi-omics sequencing platforms.

Thermo Fisher demonstrates 8-minute proteomic sample throughput on the Orbitrap Astral, quantifying over 8,000 distinct protein groups from minimal cell lysates to revolutionize biomarker discovery.

Danaher Corporation completes the worldwide commercial consolidation of Abcam into its Life Sciences operating segment, creating an integrated supply ecosystem spanning discovery antibodies, filtration, and chromatography resins.